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Dominant Th1 and Minimal Th17 Skewing in
Discoid Lupus Revealed by Transcriptomic
Comparison with Psoriasis
Ali Jabbari1,2, Mayte Sua´rez-Farin˜as2,3, Judilyn Fuentes-Duculan2, Juana Gonzalez4, Inna Cueto2,
Andrew G. Franks Jr5,6 and James G. Krueger2,3
Discoid lupus erythematosus (DLE) is the most common skin manifestation of lupus. Despite its high frequency
in systemic lupus in addition to cases without extracutaneous manifestations, targeted treatments for DLE are
lacking, likely because of a dearth of knowledge of the molecular landscape of DLE skin. Here, we profiled the
transcriptome of DLE skin in order to identify signaling pathways and cellular signatures that may be targeted for
treatment purposes. Further comparison of the DLE transcriptome with that of psoriasis, a useful reference given
our extensive knowledge of molecular pathways in this disease, provided a framework to identify potential
therapeutic targets. Although a growing body of data support a role for IL-17 and T helper type 17 (Th17) cells in
systemic lupus, we show a relative enrichment of IFN-g-associated genes without that for IL-17-associated genes
in DLE. Extraction of T cells from the skin of DLE patients identified a predominance of IFN-g-producing Th1 cells
and an absence of IL-17-producing Th17 cells, complementing the results from whole-skin transcriptomic
analyses. These data therefore support investigations into treatments for DLE that target Th1 cells or the IFN-g
signaling pathway.
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INTRODUCTION
Lupus erythematosus (LE) is a heterogeneous disease whose
hallmark is the formation of circulating autoantibodies. Sys-
temic LE (SLE) is a multiorgan form of LE with manifestations
that can variably affect the skin, joints, kidneys, and central
nervous system, among other organ systems. The etiology of
SLE is multifactorial, and both genetic and environmental
influences are believed to contribute to it.
The most common specific skin manifestation of lupus is
discoid LE (DLE), and its presence is one of the 11 American
College of Rheumatology diagnostic criteria for SLE (Tan et al.,
1982). DLE represents up to 80% of all cutaneous lupus cases
(Gronhagen et al., 2011), and this skin manifestation is notable
for its tendency to cause disfigurement, alopecia, and scarring
(Rothfield et al., 1963). Approximately one in four patients
with SLE have DLE (Uramoto et al., 1999; Sanchez et al.,
2011) and, in some DLE cases, the skin can be the only end-
organ affected without extracutaneous involvement. Intere-
stingly, a recent observational, population-based study of over
1,000 cutaneous lupus patients noted an overall rate of
progression to SLE of 18% within a 3-year follow-up period
(Gronhagen et al., 2011). The ease of sampling affected skin
potentially makes DLE a convenient and accessible model to
study end-organ pathology in SLE.
Currently, antimalarials are the most commonly used
systemic treatment for cutaneous lupus, despite the fact that
the mechanism of action of this class of drugs is not
completely understood (Wallace et al., 2012). Furthermore,
a need exists for new treatments because many patients do not
respond to antimalarials or other available immunosup-
pressants. Insights into the pathophysiology of damage to
this end organ have the potential to identify therapeutic targets
and new treatments.
Initial studies have focused on the types of cells present in
DLE lesions. Histopathologically, a dense perivascular, peri-
adnexal lymphocytic infiltrate with interface dermatitis can be
appreciated, with most analyses indicating that CD4 T cells
are the predominant inflammatory cell type. A growing body
of evidence supports the importance of T helper type 17
(Th17) CD4 T cells in SLE pathogenesis (Pan et al., 2008;
Brajac et al., 2010; Chen et al., 2010; Henriques et al., 2010;
Mok et al., 2010; Shah et al., 2010; Alunno et al., 2012),
ORIGINAL ARTICLE
1Department of Dermatology, College of Physicians and Surgeons, Columbia
University, New York, New York, USA; 2Laboratory for Investigative
Dermatology, The Rockefeller University, New York, New York, USA; 3Center
for Clinical and Translational Science, The Rockefeller University, New York,
New York, USA; 4Translational Technology Core Laboratory, The Rockefeller
University, New York, New York, USA; 5The Ronald O. Perelman Department
of Dermatology, New York University School of Medicine, New York, New
York, USA and 6Division of Rheumatology, Department of Medicine, New
York University School of Medicine, New York, New York, USA
Correspondence: James G. Krueger, The Rockefeller University, 1230 York
Avenue, Krueger Lab, New York, New York 10065, USA.
E-mail: jgk@rockefeller.edu
Received 19 February 2013; revised 29 April 2013; accepted 15 May 2013;
accepted article preview online 14 June 2013; published online 18 July 2013
Abbreviations: DLE, discoid lupus erythematosus; GSEA, Gene Set Enrichment
Analysis; LE, lupus erythematosus; RT–PCR, reverse transcriptase–PCR; SLE,
systemic lupus erythematosus; Th, T helper
& 2014 The Society for Investigative Dermatology www.jidonline.org 87
although comparisons of the relative frequencies of T helper
(Th) subtypes in DLE have not been rigorously undertaken.
Targeting the specific subset of T cells or their effector cytokines
that are critical to the pathogenesis of DLE is a strategy for the
design of new therapeutic agents, as has been done for other
cutaneous autoimmune diseases. Psoriasis, now known to be
a predominantly Th17-mediated disease, is a clear example;
ustekinumab, an mAb that blocks Th17- and Th1-related path-
ways (Leonardi et al., 2008; Papp et al., 2008), was recently
approved for the treatment of psoriasis, and two IL-17/Th17
pathway inhibitors were recently shown to be efficacious in
clinical trials (Leonardi et al., 2012; Papp et al., 2012).
We were interested in identifying global perturbations in
immune-related pathways or immune cell signatures that
were present in skin lesions of DLE. Here, we provide a
molecular description of the transcriptome of DLE. Analysis of
activated gene expression pathways was performed, identify-
ing a preponderance of immune-related pathway activation.
Next, we compared the transcriptional profile of DLE skin
with psoriasis, the most well-characterized autoimmune skin
disease to date and therefore a useful basis for comparison.
Our interest was to characterize the type of T cells infiltrating
DLE lesions. Our reference skin disease, psoriasis, is caused
by interactions between skin keratinocytes and T cells that
make up the Th17, Th22, and Th1 subsets. In contrast, we
report relatively minimal Th17 signatures, as ascertained by
Gene Set Enrichment Analysis (GSEA), gene expression, and
T-cell protein production, but rather skewing toward a
predominantly Th1 signature in whole skin and infiltrating
T cells in DLE. We thus provide a rationale to exploring
targeting cells and molecular pathways associated with the
formation and function of Th1 cells.
RESULTS
In order to define the transcriptional profile of discoid lupus
skin lesions, we first performed punch biopsies of the affected
skin of discoid lupus patients and healthy control patients.
RNA extracted from skin samples was processed and hybri-
dized to GeneChip Human Genome U133 2.0 microarrays.
Gene lists of differentially expressed genes between DLE and
normal skin were generated using criteria of 42-fold change
and o0.05 false discovery rate and subsequently interrogated
using Ingenuity Pathway Analysis. The majority of pathways
were indicative of changes in immune-related pathways and
immune cell signatures (Figure 1a). Upregulated pathways
include that for ‘‘SLE signaling’’ and ‘‘IFN signaling,’’ con-
sistent with reports of a prominent IFN signature in the
peripheral blood of patients with SLE (Baechler et al., 2003;
Bennett et al., 2003; Kirou et al., 2004; Bauer et al., 2006) as
well as the upregulated IFN genes in DLE lesions reported
by others (Wenzel et al., 2005b). Quantitative PCR confir-
mations supported increased cellular signatures of T cells
(CD3D), CD8 T cells (CD8A, GZMB, GNLY), B cells (IGJ),
macrophages (CD163), natural killer cells (KLRK1, KLRD1),
and dendritic cells (CD86, SIGLEC1, MR1) as well as IFN
(MX1, OASL, STAT1), IL-15, and IL-1b signatures. DLE skin,
therefore, is marked by potent induction of immune pathways
and immune cell signatures.
Because of the high number of pathways and immune cell
signatures that were present in our analysis of the DLE
transcriptional profile, a well-described inflammatory skin
disease, psoriasis, was used as a reference for comparison.
Although histological and immunohistochemical features of
the two diseases are well known, a comparative tissue-level
appraisal of these disease entities has not previously been
done and provides context to our molecular analyses. Histo-
logical and immunohistochemical comparisons highlighted
differences in these skin diseases (Figure 2). In psoriasis, a
superficial perivascular infiltrate is appreciated on hematox-
ylin and eosin staining with overlying hyperplasia of the
epidermis, whereas prominent dermal edema and inflamma-
tion of the dermoepidermal junction is appreciated in DLE.
DLE was noted to have more inflammatory cell infiltrates of
CD3þ and CD11cþ cells. Also, differences were noted in
cellular localization; CD8þ infiltrates were predominantly
epidermal in psoriasis compared with a dermal preponder-
ance in DLE (Figure 2). It is clear that, despite both entities
being autoimmune skin diseases, differences exist in the
relatively quantities and tissue localizations of immune cells.
A global comparison of the transcriptional profiles of DLE
and psoriasis was performed to identify contrasting elements.
DLE and psoriasis samples formed distinct groups on Principal
Components Analysis plots, indicative of distinct molecular
profiles (Figure 3a). By comparing ‘‘DLE versus normal skin’’
and ‘‘psoriasis versus normal skin,’’ we found that 591 genes
were uniquely upregulated and 358 genes were uniquely
downregulated in DLE; in psoriasis, 770 genes were uniquely
upregulated and 989 genes were uniquely downregulated
(Figure 3b). A heat map of the most differentially expressed
genes between DLE and psoriasis, generated by directly
comparing DLE and psoriasis, highlighted the major differ-
ences in the transcriptomes of these diseases (Figure 3c). For
example, genes that were among the most highly expressed in
psoriasis when compared with DLE included DEFB4A,
S100A12 and IL8, the genes associated with the IL-17-
regulated pathway (Guttman-Yassky et al., 2008), and
quantitative reverse transcriptase–PCR (RT–PCR) confirmed
this relationship (Supplementary Figure S1 online). In total,
these data indicate that DLE has a distinct molecular profile
when compared with psoriasis, and also indicate that these
diseases are the result of distinct pathological mechanisms.
In order to further define differences in Th-associated
cytokine pathways, such as the IL-17 pathway, differentially
expressed genes between DLE and psoriasis were then inter-
rogated with GSEA (Subramanian et al., 2005). The goal of
GSEA is to determine whether a defined set of genes
(described below) are overrepresented at the extremes (either
increased or decreased expression) throughout a reference
gene list (in the analysis here, we use the gene list from DLE
vs. psoriasis). The degree to which a gene set is
overrepresented at the extremes of a reference gene list is
reflected in an enrichment score. Because we were interested
in Th-associated cytokine pathways, gene sets from
keratinocytes cocultured with the Th cytokines IL-17, IFN-g,
and IL-22 (Nograles et al., 2008) were used in this analysis. In
addition, we included gene sets from keratinocytes cocultured
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Figure 1. Transcriptomic analysis of discoid lupus erythematosus (DLE). (a) Selected top canonical pathways from interrogation of the DLE (n¼ 7) versus normal
transcriptome (n¼ 13) with Ingenuity Pathway Analysis. (b) Quantitative reverse transcriptase–PCR (RT–PCR) of selected upregulated genes in the DLE versus
normal transcriptome corresponding to IFN-associated genes (MX1, OASL, STAT1), immune cell–associated genes, and selected cytokines in DLE (n¼ 7) and
normal (n¼6) samples. Genes were normalized to human ribosomal acidic protein. Box and whisker plots (middle line: median; box: lower to upper quartile;
whiskers: minimum and maximum). *Po0.05, **Po0.005, ***Po5104, ****Po5 10 5, wPo5 106, wwPo5107, wwwwPo5109. DC, dendritic
cell; NK, natural killer cell; PRR, pattern recognition receptor; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
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with tumor necrosis factor (Zaba et al., 2009), as inhibiting the
tumor necrosis factor signal is an efficacious form of treatment
in patients with psoriasis, or IFN-a (Mee et al., 2007), a
signature cytokine in the peripheral blood of SLE patients and
identified in DLE lesions (Baechler et al., 2003; Bennett et al.,
2003; Kirou et al., 2004; Bauer et al., 2006). GSEA analysis
was conducted for the differentially expressed genes between
DLE and psoriasis; the set of genes with increased expression
in DLE when compared with psoriasis showed enrichment of
the following sets of genes: upregulated genes in keratinocytes
cocultured with IFN-a or IFN-g (Table 1). In contrast, the set of
genes with decreased expression in DLE when compared with
psoriasis (therefore higher expression in psoriasis compared
with DLE) showed enrichment of the upregulated gene sets
from keratinocytes cocultured with IL-17, IL-22, or tumor
necrosis factor (Table 2). In sum, the GSEA analysis is
consistent with prior reports implicating IL-17, IL-22, and
tumor necrosis factor pathways in the pathogenesis of psoriasis
and type I IFN for DLE, but further supports that activation of
the IFN-g pathway is more characteristic of DLE than is
activation of the IL-17 pathway.
One potential caveat of our GSEA analysis is that the IL-17-
associated signature, however, may be active in DLE, but not
to a sufficient extent to overcome or render statistically
insignificant the signal for psoriasis. Because of this possibility,
we next examined the expression of the primary Th-associated
cytokines. Quantitative RT–PCR for IFN-g, IL-17A, and IL-22,
corresponding to Th1, Th17, and Th22 cells, respectively,
revealed substantial mRNA expression of these cytokines in
psoriasis skin samples (Figure 4a), consistent with prior reports
for psoriasis (Lowes et al., 2008; Jabbari et al., 2011). In
contrast, DLE skin samples expressed relatively low levels of
IL-17A and IL-22 and high levels of IFN-g. IL-13 expression
was not detected in psoriasis or DLE samples (data not shown).
These data support a Th1/Th17/Th22 mixed signature in
psoriasis, but a predominantly Th1-skewed signature, with
minimal Th17 activation, for DLE.
H&E
CD3
CD11c
CD8
PsoriasisNormal DLE
Figure 2. Microscopic and immunohistologic comparison of discoid lupus erythematosus (DLE) and psoriasis. Skin sections from patients with DLE, psoriasis, or
healthy control patients were stained with hematoxylin and eosin (H&E) or were subjected to immunohistochemistry with antibodies specific for CD3, CD11c, or
CD8. Scale bar ¼ 100mm.
Table 1. GSEA analysis of upregulated genes in DLE
compared with psoriasis
Name Size ES NES P-value FDR
KC IFNa UP1 28 0.70 2.23 0.000 0.000
KC IFNg UP2 965 0.29 1.46 0.000 0.047
Abbreviations: DLE, discoid lupus erythematosus; ES, enrichment score;
FDR, false discovery rate; GSEA, Gene Set Enrichment Analysis; KC,
keratinocyte; NES, normalized enrichment score.
1KC IFNa UP are keratinocytes cultured with IFN-a (Mee et al., 2007),
genes with increased expression.
2KC IFNg UP are keratinocytes cultured with IFN-g (Nograles et al., 2008),
genes with increased expression.
A Jabbari et al.
Dominant Th1 and Minimal Th17 Skewing in DLE
90 Journal of Investigative Dermatology (2014), Volume 134
In order to assess the relative frequencies of T cells among
Th subsets in DLE lesions, we isolated T-cell emigrants from
skin samples from patients with DLE and psoriasis for
comparison. T cells were stained for intracellular IFN-g and
IL-17A after in vitro stimulation with phorbol-12-myristate-13-
acetate and ionomycin. A detectable population of CD4
T cells from psoriasis skin samples were able to readily produce
both IFN-g and IL-17A, whereas only IFN-g producing CD4
T cells from DLE skin were appreciated in DLE lesions
(Figure 4b). All DLE samples hado1% CD4 T cells expressing
IL-17, whereas psoriasis samples analyzed in parallel and
previously published data (Lowes et al., 2008) demonstrated
substantial IL-17 production by lesional CD4 T cells
(Supplementary Figure S2 online). These data demonstrating
IFN-g protein elaboration support that the Th infiltrate of DLE
skin samples predominantly consist of Th1 cells.
DISCUSSION
DLE is a cutaneous manifestation of lupus that causes scarring
and disfigurement. Treatment usually requires systemic immu-
nosuppressive agents with ill-defined mechanisms of action,
the potential for harmful side effects, and a requirement for
frequent laboratory surveillance. In many cases, available
systemic agents are unable to adequately control the disease.
There is therefore a critical need for the development of a
targeted therapeutic agent with a favorable side-effect profile.
The rational identification of potential therapeutic targets
requires a well-developed understanding of the pathogenesis
of disease. Psoriasis is an example of an autoimmune skin
disease in which our growing understanding of the cytokines
and T cells critical to the disease have led to the identification
of new treatment targets. The biologics that inhibit IL-17- and
IL-22-mediated signaling, recently identified to play critical
roles in this disease (Nestle et al., 2009), are at various stages
of development (Leonardi et al., 2012; Papp et al., 2012), with
some now entering the final phases of clinical trials (http://
clinicaltrials.gov).
A molecular characterization of DLE, however, has not
been carried out to the same extent as that for psoriasis. The
current knowledge of DLE pertains to targeted assessments of
specific signaling pathways and has been most well described
Table 2. GSEA analysis of downregulated genes in DLE
compared with psoriasis
Name Size ES NES P-value FDR
KC IL17 UP1 46  0.76 2.81 0.000 0.000
KC IL22 UP2 11  0.61 1.60 0.036 0.027
KC TNF UP3 503  0.29 1.52 0.000 0.048
Abbreviations: DLE, discoid lupus erythematosus; ES, enrichment score;
FDR, false discovery rate; GSEA, Gene Set Enrichment Analysis; KC,
keratinocyte; NES, normalized enrichment score; TNF, tumor necrosis
factor.
1KC IL17 UP are keratinocytes cultured with IL-17A (Nograles et al., 2008),
genes with increased expression.
2KC IL22 UP are keratinocytes cultured with IL-22 (Nograles et al., 2008),
genes with increased expression.
3KC TNF UP are keratinocytes cultured with TNF-a (Zaba et al., 2009),
genes with increased expression.
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Figure 3. Transcriptomic comparison between discoid lupus erythematosus
(DLE) and psoriasis. (a) Principal components (PC) analysis plot comparing
DLE (n¼ 7), psoriasis (n¼ 18), and normal control (n¼ 13) samples. (b) Venn
diagram comparing upregulated and downregulated genes from DLE versus
normal skin (DLE) and psoriasis versus normal skin. (c) Heat map comparing
the most upregulated and downregulated genes in DLE versus psoriasis.
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for type I IFNs (Wenzel et al., 2005a,b, 2009; Braunstein et al.,
2012). Cytokines associated with specific T-cell subsets have
been explored in two separate prior studies (Stein et al., 1997;
Toro et al., 2000), although their results conflicted with each
other and were published before the discovery of the Th17
and Th22 T-cell subsets.
Recent descriptions of the presence of Th17 cells in the
blood of DLE patients (Balanescu et al., 2010), as well as a
growing literature on the role of Th17 cells in SLE (Balanescu
et al., 2010; Chen et al., 2010; Henriques et al., 2010; Mok
et al., 2010; Shah et al., 2010; Kleczynska et al., 2011),
seemed to support the hypothesis that Th17 cells would be
present at appreciable numbers and may be playing a role in
the development of discoid lesions—our data illustrating
minimal Th17 involvement in DLE lesions were unexpected.
Several reports have described the presence of IL-17-related
activity or signals in DLE lesions by immunohistochemistry
(Tanasescu et al., 2010; Oh et al., 2011) or in the serum of
DLE patients (Balanescu et al., 2010). IL-17-related markers
have also been reported as upregulated compared with
healthy controls in the serum of SLE patients in some (Shah
et al., 2010; Zhao et al., 2010), but not all (Brajac et al., 2010;
Higgs et al., 2012) studies. In a few cases, enhanced numbers
of Th17 cells were only significantly increased in those
patients with higher SLEDAI (Systemic Lupus Erythematosus
Disease Activity Index) scores, a research instrument that
integrates clinical data and laboratory results to assess SLE
activity and identify SLE flares (Dolff et al., 2010). The results
of our analysis, however, indicated that the expected Th17-
associated gene set was minimally enriched in our
comparative DLE data, and this was further corroborated by
the absence of IL-17-producing infiltrating T cells in DLE.
The study presented here provides a global description of
gene expression in lesional skin of discoid lupus; although
others have used customized microarray technologies in the
examination of specific aspects of DLE (Chang et al., 2011),
we found no substantial global description of lesional skin in
DLE in the literature to date. By comparing our transcriptomic
data to that of psoriasis, an autoimmune skin disease whose
gene expression profile in skin has been described in dozens
of subjects (Bowcock et al., 2001; Zhou et al., 2003;
Gudjonsson et al., 2009; Suarez-Farinas et al., 2010; Jabbari
et al., 2012), we were able to identify signatures that may be
useful in the pursuit of novel therapeutics. Our gene
expression and protein data do not support the use of an IL-
17-modulating strategy in the treatment of this disease. Rather,
these data invite exploring interventions that target IFN-g or
Th1 cell infiltration in the treatment of DLE.
Therapeutic agents that target IFN signaling are currently in
development for use in autoimmune diseases. Inhibitors of
proximal signaling mediators of IFN-g signaling, including
JAK1 and JAK2, have recently been approved for the treatment
of myelofibrosis (Verstovsek et al., 2010; Harrison et al., 2012;
Verstovsek et al., 2012). In addition, some studies have
examined the use of these small-molecular inhibitors in
topical form (Fridman et al., 2011), which would be
especially useful in the context of DLE treatment in the
absence of SLE.
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Figure 4. Comparison of T helper subsets in discoid lupus erythematosus
(DLE) and psoriasis. (a) Quantitative reverse transcriptase–PCR (RT–PCR)
comparison of T helper subset–associated cytokines in DLE and psoriasis.
*Po0.05, **Po5105, wPo5106. (b) Intracellular cytokine staining of
CD4 T cells extracted from lesions from patients with DLE (n¼4) or psoriasis
(n¼ 4) for IFN-g or IL-17A and stimulated with (þ PMA/I, right column) or
without ( PMA/I, left column) phorbol myristate acetate ionomycin (PMA)
and ionomycin (I). Numbers are percentages of CD3þCD4þ events positive
for either IFN-g or IL-17A.
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It is unclear whether similar pathogenic mechanisms are
present in other affected end organs in lupus, and it is possible
that systemic inhibition of pathways activated in DLE may be
useful in the treatment of SLE. Interestingly, some immuno-
modulating biologics that are currently in use for the treatment
of psoriasis additionally address extracutaneous manifestations
of the disease. Another possibility is that DLE is a marker of a
global inflammatory profile in a subset of SLE patients, and the
presence of DLE identifies those SLE patients who have one
particular molecular pattern of end-organ pathology that is
distinct from that seen in SLE patients without DLE. In this
scenario, molecular profiling of skin lesions may be useful to
identify therapeutic targets in a specific subset of SLE patients.
Genetic studies have defined SLE-associated single-nucleotide
polymorphisms that are enriched in SLE patients with DLE,
supporting the fact that the presence of DLE may be indicative
of a particular ‘‘flavor’’ of SLE (Sanchez et al., 2011).
Furthermore, whether the pathogenic mechanisms in DLE
lesional skin are different in the context of systemic disease or
cutaneous involvement alone will require further studies with
adequate patient samples to power this form of stratification.
Although our study does not stratify based on the presence of
SLE, our data provide a global description of gene expression
in DLE skin and provide a springboard to future work
potentially culminating in a specific, efficacious treatment.
MATERIALS AND METHODS
Skin samples
A total of 11 patients with active DLE were enrolled in the study
(Supplementary Table S2 online). Punch biopsy and shave biopsy
specimens of psoriasis (n¼ 5) and normal (n¼ 3) skin samples were
from patients with active moderate-to-severe disease or healthy
subjects, respectively. Additional sample data from prior studies were
added as indicated in the text or Supplementary Methods online.
All procedures were performed under Institutional Review Board–
approved protocols at New York University or at the Rockefeller
University Hospital. Punch biopsy specimens were frozen in
optimal cutting temperature medium for immunohistochemistry or
flash frozen with liquid nitrogen for RNA extraction. Shave
biopsy specimens were prepared for T-cell emigrant isolation and
functional cytokine expression (see below) as previously described
(Lowes et al., 2008).
Sample preparation for RT–PCR and gene chip analysis
Total RNA was extracted from flash-frozen punch biopsy samples
using the RNeasy Mini Kit (Qiagen, Valencia, CA). DNA was
removed by on-column DNase digestion by the RNase-free DNase
Set (Qiagen).
DNA microarray analysis
Human Genome U133A 2.0 gene chips (Affymetrix, Santa Clara, CA)
were used for this study. The U133A 2.0 array includes more
than 22,000 probe sets to analyze expression level of more than
18,400 transcripts, including 12,681 genes with known identity.
Descriptions of methods for total RNA preparation for microarray
hybridization, microarray data analysis, and Ingenuity Pathway
Analysis (www.ingenuity.com) have been included in the
Supplementary Materials online.
Quantitative RT–PCR analysis
Quantitative PCR was performed using RNA or amplified cDNA
using Taqman (Applied Biosystems, Carlsbad, CA) gene expression
assays. Predesigned primer and probe sets were purchased from
Applied Biosystems. Data normalized to human acidic ribosomal
protein housekeeping gene were quantified by software provided with
Applied Biosystems. Statistical analysis compared log2-transformed,
normalized values from DLE and psoriasis samples by unpaired two-
tailed Student’s t-test.
Functional cytokine expression, intracellular cytokine staining,
and flow cytometry
Shave biopsy specimens were cultured for 2 hours in 0.5% dispase
(Sigma Aldrich, St Louis, MO) to separate the epidermis and dermis.
Dermal T cells were obtained by culturing the dermis for 3 days in
RPMI-1640 (Gibco-BRL Life Technologies, Carlsbad, CA) supplemen-
ted with 10% human pooled serum (Mediatech, Manassas, VA), and
1% 1 M HEPES buffer (Sigma Aldrich); one DLE sample did not yield
sufficient number of live cells to perform further analyses. T cells were
cultured for 4 hours with 10mg ml 1 brefeldin A with or without
25 ng ml 1 phorbol myristate acetate and 2mg ml 1 ionomycin (all
from Sigma Aldrich). Cells were frozen in 10% DMSO (ATCC,
Manassas, VT) in RPMI-1640 (Gibco-BRL Life Technologies) with
1 mM HEPES buffer (Sigma Aldrich), 0.1% gentamicin (Gibco-BRL Life
Technologies), and 5% normal human serum (C-Six Diagnostics,
Germantown, WI). Frozen cells were thawed, washed, and subjected
to an intracellular staining protocol. Briefly, cells were stained for
30 minutes at room temperature with antibodies specific for human
CD3 and CD4. After washing with FACS Buffer, cells were permeabi-
lized and stained with antibodies specific for human IFN-g and IL-17A.
Samples were acquired using an LSRII (BD Biosciences, Rockville, MO)
and analyzed using FlowJo software (Tree Star, Ashland, OR).
Immunohistochemistry
Frozen sections were stained with hematoxylin (Fisher Scientific,
Pittsburgh, PA) and eosin (Shandon, Pittsburgh, PA). As previously
described for immunohistochemistry (Jabbari et al., 2012), frozen
sections were blocked with 10% normal horse serum, and
endogenous peroxidases were quenched by incubation with diluted
hydrogen peroxide (1:10 dilution of 3% hydrogen peroxide). Sections
were incubated overnight at 4 1C with primary mAbs. Biotin-labeled
horse anti-primary antibodies were used for secondary binding, and
thereafter the signals were amplified with avidin–biotin complex (Vector
Laboratories, Burlingame, CA). Subsequently, the sections were devel-
oped using chromogen 3-amino-9-ethylcarbazole (Sigma-Aldrich).
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